Abstract
Background: Prostate cancer (PCa) patients shall develop eventually incurable bone metastasis. Although advanced prostate cancer is the best known example of androgen- dependent neoplasia, PCa patients after an excellent clinical response to adrogen ablation therapies (medical or surgical castration) will ultimately become castration resistant (CRPC).
Methods: Analysis of cell-cell interactions within the sites of osteoblastic metastasis has revealed that survival factors (inhibitors of chemotherapy-induced apoptosis and androgen deprivation/medical or surgical castration-induced apopptosis) for prostate cancer cells are activated, locally.
Results: The analysis of these cell-cell interactions between metastatic PCa cells and host tissue (bone) revealed that insulin-like growth factor I, transforming growth factor beta 1 (TGFβ1), interleukin 6 (IL-6) are the most important survival factors for prostate cancer cells residing in bones. Suppression of the bioavailability of such survival factors which can achieved by the administration of dexamethasone plus somatostatin analogues (anti-survival factor therapy: ASF therapy) was proven an effective hormonal manipulation for the treatment of CRPC.
Conclusion: The present review provides an update on bone microenvironment cell-cell interactions forming the concept of the ASF therapy for CRPC.
Keywords: Bone metastasis, prostate cancer, targeted therapies, tumor microenvironment, anti-survival factor therapy (ASF).
Graphical Abstract
Clinical Cancer Drugs
Title:Castration-resistant Prostate Cancer: The Targeting of Bone Microenvironment-related Survival Factors For Prostate Cancer Cells
Volume: 3
Author(s): Dimitrios Karamanolakis, Athanasios Armakolas and Michael Koutsilieris
Affiliation:
Keywords: Bone metastasis, prostate cancer, targeted therapies, tumor microenvironment, anti-survival factor therapy (ASF).
Abstract: Background: Prostate cancer (PCa) patients shall develop eventually incurable bone metastasis. Although advanced prostate cancer is the best known example of androgen- dependent neoplasia, PCa patients after an excellent clinical response to adrogen ablation therapies (medical or surgical castration) will ultimately become castration resistant (CRPC).
Methods: Analysis of cell-cell interactions within the sites of osteoblastic metastasis has revealed that survival factors (inhibitors of chemotherapy-induced apoptosis and androgen deprivation/medical or surgical castration-induced apopptosis) for prostate cancer cells are activated, locally.
Results: The analysis of these cell-cell interactions between metastatic PCa cells and host tissue (bone) revealed that insulin-like growth factor I, transforming growth factor beta 1 (TGFβ1), interleukin 6 (IL-6) are the most important survival factors for prostate cancer cells residing in bones. Suppression of the bioavailability of such survival factors which can achieved by the administration of dexamethasone plus somatostatin analogues (anti-survival factor therapy: ASF therapy) was proven an effective hormonal manipulation for the treatment of CRPC.
Conclusion: The present review provides an update on bone microenvironment cell-cell interactions forming the concept of the ASF therapy for CRPC.
Export Options
About this article
Cite this article as:
Karamanolakis Dimitrios, Armakolas Athanasios and Koutsilieris Michael, Castration-resistant Prostate Cancer: The Targeting of Bone Microenvironment-related Survival Factors For Prostate Cancer Cells, Clinical Cancer Drugs 2016; 3 (1) . https://dx.doi.org/10.2174/2212697X03666151203202934
DOI https://dx.doi.org/10.2174/2212697X03666151203202934 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical Aspects to be Considered Prior to Large-Scale Production of Peptides
Current Protein & Peptide Science Circulating Levels of VCAM and MMP-2 May Help Identify Patients with More Aggressive Prostate Cancer
Current Cancer Drug Targets Aging and DNA Methylation
Current Chemical Biology Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro
Current Medicinal Chemistry Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Current Topics in Medicinal Chemistry Additive Effect of MCP in Combination with Cefotaxime Against Staphylococcus aureus
Medicinal Chemistry Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms of Anti-cancer Activities of β-elemene: Targeting Hallmarks of Cancer
Anti-Cancer Agents in Medicinal Chemistry New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Antiproliferative and Antioxidant Potential of Leaf and Leaf Derived Callus Extracts of Aerva lanata (L.) Juss. Ex Schult. Against Human Breast Cancer (MCF-7) Cell Lines
The Natural Products Journal PET Imaging for Gene & Cell Therapy
Current Gene Therapy New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism
MicroRNA Structure-Function Based Design of Small Molecule Inhibitors Targeting Rho Family GTPases
Current Topics in Medicinal Chemistry Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Patented Novelties in Immunoisolation for the Treatment of Endocrine Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)